We are live on
!
Find out more
SAM
Sectoral Asset Management Portfolio holdings
AUM
$121M
1-Year Est. Return
73.47%
This Fund
S&P 500
This Quarter
Est. Return
+3.48%
1 Year Est. Return
+73.47%
3 Year Est. Return
+165.77%
5 Year Est. Return
+169.27%
10 Year Est. Return
+1,136.49%
AUM
$942M
AUM Growth
+$47.5M
(+5.3%)
Cap. Flow
+$57.7M
Cap. Flow
% of AUM
6.13%
Top 10 Holdings %
Top 10 Hldgs %
36.92%
Holding
174
New
107
Increased
33
Reduced
23
Closed
6
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
CELG
Celgene Corp
CELG
|
+$22.8M |
| 2 |
FOLD
Amicus Therapeutics
FOLD
|
+$16.4M |
| 3 |
Collegium Pharmaceutical
COLL
|
+$15.5M |
| 4 |
Vertex Pharmaceuticals
VRTX
|
+$13.7M |
| 5 |
AERI
Aerie Pharmaceuticals
AERI
|
+$10.4M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Sarepta Therapeutics
SRPT
|
+$24.4M |
| 2 |
Molina Healthcare
MOH
|
+$17.5M |
| 3 |
EXAS
Exact Sciences
EXAS
|
+$14.2M |
| 4 |
PRAH
PRA Health Sciences, Inc.
PRAH
|
+$13.9M |
| 5 |
ALXN
Alexion Pharmaceuticals
ALXN
|
+$11.5M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 84.63% |
| 2 | Industrials | 0.89% |
| 3 | Technology | 0.84% |
| 4 | Financials | 0.02% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
76
Incyte
INCY
$25.4B
| $768K | 0.08% |
11,113
-68,132
| -86% | -$4.68M |
|
77
Dr. Reddy's Laboratories
RDY
$9.8B
| $747K | 0.08% |
107,985
| – | – |
|
78
HCA Healthcare
HCA
$90.6B
| $735K | 0.08% |
+5,286
| New | +$658K |
|
79
Ultragenyx Pharmaceutical
RARE
$2.46B
| $691K | 0.07% |
+9,047
| New | +$736K |
|
|
WCG
80
DELISTED
Wellcare Health Plans, Inc.
WCG
| $603K | 0.06% |
+1,881
| New | +$534K |
|
81
Biogen
BIIB
$30.9B
| $587K | 0.06% |
+1,662
| New | +$572K |
|
82
Regeneron Pharmaceuticals
REGN
$72.9B
| $554K | 0.06% |
+1,370
| New | +$521K |
|
|
LOXO
83
DELISTED
Loxo Oncology, Inc
LOXO
| $546K | 0.06% |
+3,195
| New | +$537K |
|
84
Viatris
VTRS
$20.8B
| $524K | 0.06% |
+14,329
| New | +$538K |
|
85
McKesson
MCK
$104B
| $510K | 0.05% |
+3,842
| New | +$501K |
|
|
ATHN
86
DELISTED
Athenahealth, Inc.
ATHN
| $498K | 0.05% |
+3,724
| New | +$558K |
|
87
Heron Therapeutics
HRTX
$93.4M
| $482K | 0.05% |
+15,243
| New | +$568K |
|
88
Coherus Oncology
CHRS
$217M
| $462K | 0.05% |
+27,987
| New | +$496K |
|
|
DERM
89
DELISTED
Dermira, Inc.
DERM
| $457K | 0.05% |
+41,902
| New | +$423K |
|
90
Cerus
CERS
$575M
| $437K | 0.05% |
+60,576
| New | +$440K |
|
|
BLUE
91
DELISTED
bluebird bio
BLUE
| $432K | 0.05% |
+228
| New | +$471K |
|
|
HMSY
92
DELISTED
HMS Holdings Corp.
HMSY
| $404K | 0.04% |
+12,307
| New | +$356K |
|
|
KALV
93
DELISTED
KalVista Pharmaceuticals
KALV
| $388K | 0.04% |
+17,551
| New | +$237K |
|
94
Danaher
DHR
$138B
| $386K | 0.04% |
+4,011
| New | +$365K |
|
95
Stryker
SYK
$135B
| $367K | 0.04% |
+2,066
| New | +$353K |
|
|
AKCA
96
DELISTED
Akcea Therapeutics Inc
AKCA
| $363K | 0.04% |
+10,356
| New | +$313K |
|
97
Intuitive Surgical
ISRG
$127B
| $359K | 0.04% |
+1,878
| New | +$333K |
|
98
Universal Health Services
UHS
$10.2B
| $359K | 0.04% |
+2,811
| New | +$345K |
|
|
MNTA
99
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
| $354K | 0.04% |
+13,458
| New | +$364K |
|
|
SRRA
100
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
| $343K | 0.04% |
5,042
| – | – |
|
Similar funds
RIP
LFWA
CF
WIM
MW
AFC
AAA
TGM
Sectoral Asset Management's Q3 2018 Portfolio in Review
As of Q3 2018, Sectoral Asset Management held 174 positions worth $942M, up 5.3% from $894M the previous quarter. Its ten largest holdings account for 37% of the portfolio.
Sectoral Asset Management deployed $57.7M of net new capital in Q3 2018, opening 107 new positions and adding to 33 existing holdings. Its largest new stake was Vertex Pharmaceuticals: 76,846 shares worth $14.8M.
By sector, the portfolio is most concentrated in Healthcare at 85% of assets, down from 85% a quarter earlier, followed by Industrials and Technology.
On the sell side, the largest reduction was Sarepta Therapeutics, an estimated $24.4M trimmed.
- Sectoral Asset Management's largest Q3 2018 buy was Vertex Pharmaceuticals: 76,846 shares worth $14.8M.
- Sectoral Asset Management added most to Celgene Corp in Q3 2018, an estimated $22.8M increase.
- Sectoral Asset Management's biggest Q3 2018 reduction was Sarepta Therapeutics, cutting an estimated $24.4M.
- Sectoral Asset Management fully exited Molina Healthcare in Q3 2018, selling an estimated $17.5M.
- Sectoral Asset Management's ten largest holdings make up 37% of its $942M portfolio in Q3 2018.
- Sectoral Asset Management opened 107 new positions and closed 6 in Q3 2018.
- Sectoral Asset Management's portfolio value rose 5.3% quarter-over-quarter to $942M.
Based on Sectoral Asset Management's 13F filing for Q3 2018, filed 14 Nov 2018.